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characteristics were significantly different between control and ob/ob mice such as body weight and glucose levels. Pharmacokinetic profiles of rosiglitazone (RSG) and its metabolites, N-desmethyl rosiglitazone (N-Dm-RSG) and hydroxy rosiglitazone (OH-RSG) were plotted after 5 mg/kg dose by intravenous and oral administration in C57/B6 and ob/ob mice (Fig. 1) . Area under the plasma concentration-time curve (AUC) levels were 50.8 ± 13.7 mg·hr/ml for control and 66.6 ± 11.8 mg·hr/ml for ob/ob mice, the maximum plasma concentrations (Cmax) were 12.9 ± 1.7 mg/ml for control and 14.8 ± 1.9 mg/ml for ob/ob mice, and the time to maximum plasma concentration (Tmax) were 0.42 ± 0.13 hr for control and 0.55 ± 0.27 hr for ob/ob mice. AUC values were not significantly different (50.8 ± 13.7 mg·hr/ml for control and 66.6 ± 11.8 mg·hr/ml for ob/ob mice). Pharmacokinetics of N-desmethyl rosiglitazone (N-Dm-RSG) in ob/ob mice was different from that in control C57/B6 mice. AUC levels of ob/ob mice were higher than that of the control C57/B6 mice after oral administration (5.4 ± 0.91 mg·hr/ml for control and 9.1 ± 1.4 mg·hr/ml for ob/ob mice). Profiles of hydroxy rosiglitazone (OH-RSG) were not significantly different between ob/ob and control C57/B6 mice. The AUC values were 4.9 ± 1.8 mg·hr/ml for control and 3.7 ± 0.96 mg·hr/ml for ob/ ob mice. This study is the first pharmacokinetic profiling of rosiglitazone and its metabolites in ob/ob mice as diabetic animal model. 
